CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Handheld Radiofrequency Spectroscopy for Intraoperative Assessment of Surgical Margins during Breast‑Conserving Surgery

This policy governs coverage and medical necessity determinations for the use of handheld radiofrequency spectroscopy (e.g., MarginProbe) to assess surgical margins intraoperatively during breast-conserving surgery for members of Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyHandheld Radiofrequency Spectroscopy for Intraoperative Assessment of Surgical Margins during Breast‑Conserving Surgery

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJul 1, 2023

Next Review DateN/A

Key ActionDo not use or bill handheld radiofrequency spectroscopy (e.g., MarginProbe) for intraoperative margin assessment as it is considered not medically necessary and claims may be denied.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredOverall policy stance

0546TNot covered code

>95%Sensitivity target

~85%Specificity benchmark

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determinations

Not Medically Necessary / Not Covered

Covered when ALL of the following are met:

Policy conclusion: Handheld radiofrequency spectroscopy for intraoperative assessment of surgical margins during breast-conserving surgery (e.g., MarginProbe) is not covered / not medically necessary because available evidence is insufficient to demonstrate improvement in net health outcome.

Randomized and other studies cited show moderate sensitivity, poor specificity, no demonstrated improvement in clinically relevant outcomes (e.g., recurrence), methodological limitations (biased control arm, inadequate follow-up), and insufficient rigor in historical controls.

This service is considered not medically necessary for Commercial Products. Benefits may vary by group or contract; providers and members should consult the applicable Benefit Booklet, Evidence of Coverage, or Subscriber Agreement to determine whether this service is covered for a specific member.

Handheld radiofrequency spectroscopy (e.g., MarginProbe) for intraoperative assessment of surgical margins during breast-conserving surgery is considered not medically necessary because the evidence is insufficient to demonstrate improvement in net health outcome.

Billing Codes and Status

Not covered / Not medically necessaryCPTNot Covered

0546T

Radiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of mastectomy, with report

Provider Requirements and Billing Implications

Prior Authorization

Prior authorization is not applicable for this service. However, handheld radiofrequency spectroscopy (e.g., MarginProbe) for intraoperative assessment of breast surgical margins is considered not medically necessary under this policy and may be denied.

Affected code: 0546T (Radiofrequency spectroscopy, real time, intraoperative margin assessment)

Step Therapy

No step therapy requirements are specified for this service.

Documentation Required

Documentation and Benefit Verification

Providers must verify member-specific coverage and document medical necessity in the medical record. Check the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable benefits and limitations prior to performing the procedure. Maintain clinical documentation supporting the indication for use and rationale for any intraoperative device use.

Clinical Background

Breast-conserving surgery (lumpectomy) aims to remove localized breast cancer or ductal carcinoma in situ while achieving tumor-free margins to minimize the need for re-excision. The MarginProbe device is an intraoperative handheld radiofrequency spectroscopy probe that measures dielectric properties of excised breast tissue by touching small areas of the lumpectomy specimen; a positive reading flags a margin as suspicious and may prompt additional tissue removal. Current definitive margin assessment remains histologic examination after surgery, and available studies report only moderate sensitivity and poor specificity for MarginProbe, with no demonstrated improvement in clinically relevant outcomes such as local recurrence.

Key Definitions

MarginProbe definition

Device typeIntraoperative handheld radiofrequency spectroscopy probe (MarginProbe)

FunctionMeasures dielectric properties of excised breast tissue by touching small areas of the lumpectomy specimen to generate positive or negative readings

Intended useAdjunct for intraoperative assessment of surgical margins during breast‑conserving surgery to help identify positive margins that may prompt additional re‑excisions

Scope of applicationUsed only on the main lumpectomy specimen; not for use on cavity margins or margin shavings

Interpretation ruleAny touch that yields a positive reading designates that margin as positive and may lead to additional tissue resection

Performance benchmarks notedPolicy notes ideal device sensitivity >95% and a specificity benchmark of approximately 85%